|
Markt geschlossen -
Andere Börsenplätze
|
Nachbörslich 00:12:00 | |||
| 59.49 USD | -3.77% |
|
59.24 | -0.41% |
| 20.07. | MODERNA, INC. : Goldman Sachs bekräftigt seine neutrale Bewertung | ZM |
| 16.07. | Moderna bewertet seine Krebstherapie - die Aktie gibt dennoch nach |
Hauptkonkurrenten
| Umsatz (Y-1) | Nettogewinn (Y-1) | EBIT-Marge (Y-1) | ROE (Y-1) | ROA (Y-1) | Verschuldungsgrad (Y-1) | ||
|---|---|---|---|---|---|---|---|
| 1.94 Mrd. | -145.16% | -158.13% | -28.87% | -21.31% | 2.03x | ||
| 14.34 Mrd. | 31.41% | 34.05% | 16.13% | 12.48% | -1.09x | ||
| 9.09 Mrd. | 20.13% | 25.95% | 14.91% | 8.78% | -0x | ||
| 3.95 Mrd. | 31.29% | 39.94% | 17.59% | 11.33% | -0.18x | ||
| 15.56 Mrd. | 19.3% | 28.72% | 16.36% | 7.75% | 1.74x | ||
| 9.89 Mrd. | 13.07% | 28.69% | 7.39% | 4.5% | 0.68x | ||
| 5.14 Mrd. | 25.03% | 31.43% | 31.7% | 22.02% | -1.81x | ||
| 1.86 Mrd. | 6.24% | 5.38% | 5.01% | 2.76% | -7.32x | ||
| 3.06 Mrd. | 1.69% | 28.34% | 14.97% | 0.67% | 0.88x | ||
| 502 Mio. | -144.39% | -104.25% | - | -78.14% | -2.48x | ||
| 638 Mio. | -28.69% | -26.12% | -252.11% | -29.11% | 0.85x | ||
| 3.22 Mrd. | 10.83% | 12.71% | 5.94% | 4.79% | -1.97x | ||
| 389 Mio. | 52.64% | 41.45% | 18.91% | - | - | ||
| 150 Mio. | 66.87% | 49.52% | 39.67% | 25.58% | 1.24x | ||
| 8.83 Mrd. | 5.34% | 18.49% | 6.14% | 2.42% | 4.83x | ||
| 377 Mio. | -20.63% | -36.18% | - | - | - | ||
| 579 Mio. | 28.22% | 29.21% | 10.08% | - | -1.4x | ||
| 260 Mio. | -21.9% | -25.8% | -3.3% | - | - | ||
| 2.53 Mrd. | 47.93% | 58.98% | 39.78% | 28.06% | -1.19x | ||
| Durchschnitt | 4.33 Mrd. | -0.04% | 4.34% | -2.34% | 0.17% | -0.32x | |
| Gewichteter Durchschnitt nach Marktkapitalisierung | 7.26 Mrd. | 4.51% | 10.43% | 4.9% | 3.16% | -0.35x |
- Börse
- Aktien
- A2N9D9 Aktie
- Sektor Moderna, Inc.
- Finanzielle Vergleiche
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
MarketScreener is also available in this country: United States.
Switch edition
Bei der aktuellen länderspezifischen Edition bleiben
















